Table 2.

Association between HDAC11 expression and clinicopathologic data

Data	Total No. of case	HDAC11high No. (%)	HDAC11low No. (%)	P-value
Tissue				<0.001*
Adjacent-carcinoma tissues	21	5/21	16/21
Cancer tissue	139	92/139	47/139
Age (yr)				0.814
≤50	67	45/67	22/67
>50	72	47/72	25/72
pT stage				0.011*
pT1	43	21/43	22/43
pT2	68	52/68	16/68
pT3	27	18/27	9/27
Clinical Stage				0.017*
I	35	20/35	15/35
II	76	57/76	19/76
III	24	11/24	13/24
Nodal status				0.230
pN0	21	15/21 (71.4%)	6/21 (28.6%)
pN1	51	30/51 (58.8%)	21/51 (41.2%)
pN2	49	37/49 (75.5%)	12/49 (24.5%)
pN3	18	10/18 (55.6%)	8/18 (44.4%)
Histologic Grade				0.088
G1	33	18/33	15/33
G2	67	43/67	24/67
G3	38	30/38	8/38
HER2 status				0.027*
Negative	68	51/68	17/68
Positive	70	40/70	30/70
ER				0.032*
Negative	65	49/65	16/65
Positive	74	43/74	31/74
PR				0.183
Negative	63	38/63	25/63
Positive	76	54/76	22/76

^* P<0.05 as calculated by the χ² test.

HDAC11, histone deacetylase 11; HER2, human epidermal growth factor receptor 2.